Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CP-4055; ELACYT; UNII-TA7WJG93AR

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clavis Pharma
  • Developer Aqualis; Clavis Pharma
  • Class Antineoplastics; Arabinonucleosides; Oleic acids; Pyrimidine nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 29 Aug 2013 Discontinued - Phase-II for Acute myeloid leukaemia (combination therapy, early-stage disease, second-line or greater) in France, Germany, Norway and USA (IV)
  • 29 Aug 2013 Discontinued - Phase-III for Acute myeloid leukaemia (late-stage disease) in Australia, Belgium, Canada, France, Germany, Ireland, Italy, Norway, Poland, Romania, Spain, United Kingdom and USA (IV)
  • 01 Apr 2013 Suspended - Phase-II for Acute myeloid leukaemia (combination therapy, second-line therapy or greater, early-stage disease) in France (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top